OPM and Navigo Proteins GmbH sign a strategic collaboration agreement for the research and development of new systemic radiotherapy agents

Oncodesign Precision Medicine and Navigo Proteins GmbH sign a strategic collaboration agreement for the research and development of new systemic radiotherapy agents

Dijon (France), May 15, 2024, at 6:00pm CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of Precision Medicine applications based on the Affilin® technology platform, announce the signature of a strategic collaboration agreement for the discovery and development of new systemic radiotheranostic agents.